Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HDAC9_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HDAC9_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HDAC9_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HDAC9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HDAC9_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HDAC9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HDAC9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
GO:0032869 | Colorectum | AD | cellular response to insulin stimulus | 72/3918 | 203/18723 | 1.10e-06 | 3.68e-05 | 72 |
GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
GO:0090132 | Colorectum | AD | epithelium migration | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
GO:0010632 | Colorectum | AD | regulation of epithelial cell migration | 88/3918 | 292/18723 | 1.19e-04 | 1.75e-03 | 88 |
GO:0010631 | Colorectum | AD | epithelial cell migration | 104/3918 | 357/18723 | 1.33e-04 | 1.90e-03 | 104 |
GO:0090130 | Colorectum | AD | tissue migration | 105/3918 | 365/18723 | 2.10e-04 | 2.77e-03 | 105 |
GO:0010634 | Colorectum | AD | positive regulation of epithelial cell migration | 56/3918 | 176/18723 | 4.51e-04 | 5.03e-03 | 56 |
GO:0043542 | Colorectum | AD | endothelial cell migration | 78/3918 | 279/18723 | 2.97e-03 | 2.22e-02 | 78 |
GO:0010595 | Colorectum | AD | positive regulation of endothelial cell migration | 40/3918 | 133/18723 | 8.01e-03 | 4.73e-02 | 40 |
GO:00328681 | Colorectum | SER | response to insulin | 65/2897 | 264/18723 | 6.70e-05 | 1.53e-03 | 65 |
GO:00016671 | Colorectum | SER | ameboidal-type cell migration | 105/2897 | 475/18723 | 6.97e-05 | 1.59e-03 | 105 |
GO:19016531 | Colorectum | SER | cellular response to peptide | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
GO:00434341 | Colorectum | SER | response to peptide hormone | 93/2897 | 414/18723 | 9.61e-05 | 2.04e-03 | 93 |
GO:00901321 | Colorectum | SER | epithelium migration | 82/2897 | 360/18723 | 1.50e-04 | 2.93e-03 | 82 |
GO:00106311 | Colorectum | SER | epithelial cell migration | 81/2897 | 357/18723 | 1.87e-04 | 3.44e-03 | 81 |
GO:00713751 | Colorectum | SER | cellular response to peptide hormone stimulus | 68/2897 | 290/18723 | 2.20e-04 | 3.89e-03 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC9 | SNV | Missense_Mutation | | c.3178N>A | p.Gly1060Ser | p.G1060S | Q9UKV0 | protein_coding | tolerated(0.21) | benign(0.168) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
HDAC9 | SNV | Missense_Mutation | | c.2057N>T | p.Arg686Leu | p.R686L | Q9UKV0 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
HDAC9 | SNV | Missense_Mutation | | c.1846N>T | p.Pro616Ser | p.P616S | Q9UKV0 | protein_coding | deleterious(0.01) | possibly_damaging(0.696) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
HDAC9 | SNV | Missense_Mutation | | c.407G>C | p.Gly136Ala | p.G136A | Q9UKV0 | protein_coding | deleterious(0.04) | benign(0.164) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HDAC9 | SNV | Missense_Mutation | novel | c.2986N>T | p.Ala996Ser | p.A996S | Q9UKV0 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HDAC9 | SNV | Missense_Mutation | | c.2093C>T | p.Ser698Phe | p.S698F | Q9UKV0 | protein_coding | deleterious(0.01) | possibly_damaging(0.852) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
HDAC9 | SNV | Missense_Mutation | | c.839N>T | p.Ser280Leu | p.S280L | Q9UKV0 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
HDAC9 | SNV | Missense_Mutation | | c.1096N>T | p.Pro366Ser | p.P366S | Q9UKV0 | protein_coding | tolerated(0.33) | benign(0) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC9 | SNV | Missense_Mutation | | c.702A>C | p.Lys234Asn | p.K234N | Q9UKV0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC9 | SNV | Missense_Mutation | novel | c.2773C>T | p.Pro925Ser | p.P925S | Q9UKV0 | protein_coding | tolerated(0.07) | possibly_damaging(0.692) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | SB939 | | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | PCI-24781 | ABEXINOSTAT | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 310264675 | CUDC-101 | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | MOCETINOSTAT | MOCETINOSTAT | 23829483,26287310 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | BUTYRYLHYDROXAMIC ACID | BUTYRYLHYDROXAMIC ACID | 21874153 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | ROMIDEPSIN | ROMIDEPSIN | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PMID29671355-Compound-25 | | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SUBEROHYDROXAMIC ACID | SUBEROHYDROXAMIC ACID | 16921367 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | CUDC-101 | CUDC-101 | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VORINOSTAT | VORINOSTAT | |